Navigation Links
BGI debuts new tool 'PDXomics' for tumor xenograft research and applications
Date:7/17/2012

July 17, 2012, Shenzhen, China BGI, the world's largest genomics organization, announced today that it has successfully developed a new filtering tool, PDXomics, which performs accurate and specific classification of the mixed reads derived from the host and tumor xenografts. Through the full utilization of this robust tool, researchers could develop the specific patient-derived xenografts (PDX) and advance the oncology drug discovery, biomarker development and their future applications.

Xenograft models serve as an important tool for many areas of biomedical research, including oncology, immunology and HIV pathology. There has been a recent increase in the use of tumor-specific PDX engrafted into immune-compromised rodents such as the most common athymic nude or NOD/SCID mice for preclinical modelling. However, the progress has been greatly hampered by the contamination resulted from the inevitable mixing between the host and the xenografts.

Considering the high degree of homology between human and mouse genomes, it is very difficult to minimize the contamination by the present physical or biochemical techniques, such as conservative sectioning, cell sorting or laser capture micro-dissection. In an effort to address the problem, researchers from BGI developed a fast, accurate and specific tool to classify the xenograft-derived sequence read data.

Researchers evaluated the tool on genomic data from three pairs of xenografts and case-matched primary tumor samples. The sequence reads were directly mapped to a mixed reference-set that contains both of human genome and mouse genome. When classifying the reads located in the DNA collinear regions of human and mouse, the result showed that PDXomics could specifically filter mouse reads from the mixed reads as well as keep human's.

Currently, there are two major traditional methods for analyzing the reads: one is processing the reads set with human genome as a reference; the other is processing the reads set first with mouse genome as a reference, then removing the mapped reads and processing the remaining reads with human genome again. To evaluate the accuracy and quality of PDXomics, researchers compared the analysis results with the two traditional methods, and they found that the PDXomics could significantly reduce the false-positive rate (FPR) of identified single-nucleotide mutations, and improve the accuracy of variation detection.

Zonghui Peng, Director, DEPT. of Pharma & Biotech Cooperation, BGI, said, "Over the past two decades, the applications of PDX have made great impact on the development of translational medicine. With the rapid development of next-generation sequencing (NGS) technology, PDXomics will be a robust tool in the optimization and screening of xenograft models in the near future, with the benefits of fast turnaround time, low cost and high efficiency."


'/>"/>

Contact: Jia Liu
liujia@genomics.cn
BGI Shenzhen
Source:Eurekalert

Related biology news :

1. Tumor microenvironment helps skin cancer cells resist drug treatment
2. Researchers identify need to sample multiple tumor zones in breast cancer
3. Cancerous tumors deliver pro-metastatic information in secreted vesicles
4. Clusters of cooperating tumor-suppressor genes are found in large regions deleted in common cancers
5. A single stem cell mutation triggers fibroid tumors
6. Immune-response genes affecting breast tumor eradication
7. TGen leads new National Institutes of Health study of brain tumors
8. Dental X-rays linked to common brain tumor
9. Nanotherapy: Treating deadly brain tumors by delivering big radiation with tiny tools
10. The loss of a protein makes jump the tumor to the lymph node
11. Stanford researchers calculate global health impacts of the Fukushima nuclear disaster
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
(Date:3/23/2016)... WAKEFIELD, Massachusetts , March 23, 2016 ... kombiniert im Interesse erhöhter Sicherheit Gesichts- und ... Xura, Inc. (NASDAQ: MESG ... heute bekannt, dass das Unternehmen mit SpeechPro ... insbesondere aus der Finanzdienstleistungsbranche, wird die Möglichkeit ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... , ... June 27, 2016 , ... ... for Amgen, will join the faculty of the University of North Carolina ... professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the ...
(Date:6/24/2016)... June 24, 2016  Regular discussions on a range of ... between the two entities said Poloz. Speaking at ... Ottawa , he pointed to the country,s inflation target, ... government. "In certain ... institutions have common economic goals, why not sit down and ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche ... with peritoneal or pleural mesothelioma. Their findings are the subject of a new article ... Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
Breaking Biology Technology: